Selio Medical developed an FDA-cleared hydrogel device that seals CT-guided lung biopsy punctures before they can cause pneumothorax — a collapsed lung complication that affects up to a third of the 800,000+ such biopsies performed annually in the U.S. The post This Device Could Prevent Lung Biopsy’s Most Common — and Costly — Complication appeared first on MedCity News.

Thyme Care’s Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. The post Thyme Care Raises $125M, Launches New Oncology Parent Entity appeared first on MedCity News.

In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — eating food with gluten to see if it prompts an immune response. There are currently no FDA-approved drugs for celiac disease, but Teva’s antibody is part of a competitive race to bring patients the first one. The post Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial appeared first on MedCity News.

[Sponsored] We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring. The post Automation Didn’t Dehumanize Care. Bad Systems Did. appeared first on MedCity News.

Isolated improvements rarely translate into enterprise-wide transformation when they are layered onto outdated, inefficient workflows instead of being integrated into redesigned care delivery.  The post The Healthcare Inflection Point: AI Can’t Fix 1990s Technology appeared first on MedCity News.

HHS awarded $77 million in SAMHSA grants for substance use prevention and treatment, mental health, suicide prevention and crisis services. The post HHS Provides $77M in Grants for Substance Use Prevention, Mental Health appeared first on MedCity News.

GSK’s messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of the virus. That could be an advantage over Moderna’s recently approved mRNA flu shot, which addresses just one of those proteins. The post GSK’s Pivotal Test for mRNA Flu Vaccine Aims to Show Two Targets Are Better Than One appeared first on MedCity News.

Faster trials are not a vanity metric. They reflect an undeniable need: getting safe therapies to patients sooner. The post Breaking the Amendment Cycle: How Agentic AI Enables Smarter Clinical Trial Design and Operations appeared first on MedCity News.

August has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Humana, Merck and Mayo Clinic named new executives. There were also layoffs at organizations including MaineHealth, Cellares and Sharp HealthCare. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News.

In this episode, we’re joined by Amanda Shafton, practicing CNM and national director of midwifery at Ob Hospitalist Group. We discuss the benefits of physician/midwifery collaboration and how midwives can improve maternal health outcomes. The post MedCity FemFwd: How Midwives Can Support the Maternal Health Crisis appeared first on MedCity News.

Health tech companies made several major funding announcements in August. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in August appeared first on MedCity News.

Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations. The post First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder appeared first on MedCity News.

If AI is not one of the CEO’s top two or three priorities, the organization will produce pilots and slide decks while better-mobilized peers pull ahead and the institution’s ability to fulfill its mission erodes The post AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation appeared first on MedCity News.

A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care. The post Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up appeared first on MedCity News.

Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on MedCity News.